Cushing’s surgery: Role of the anesthesiologist

Rudin Domi
Department of Anesthesiology, Intensive Care, Emergency, and Toxicology, University Hospital Center “Mother Theresa”, Tirana, Albania

ABSTRACT

Cushing’s syndrome is a clinical situation, caused by excessive glucocorticoid level, resulting in several features such as central obesity, supraclavicular fat, “moon face,” “buffalo hump,” hyperglycemia, metabolic alkalosis, hypokalemia, poor wound healing, easy bruising, hypertension, proximal muscle weakness, thin extremities, skin thinning, menstrual irregularities, and purple striae. In the perioperative period, the anesthesiologist must deal with difficult ventilation and intubation, hemodynamic disturbances, volume overload and hypokalemia, glucose intolerance, and diabetes, maintaining the blood cortisol level and preventing the glucocorticoid deficiency. This syndrome is quite rare and its features make these patients very difficult to the anesthesiologist.

Key words: Adrenalectomy, anesthesia, Cushing’s syndrome

EPIDEMIOLOGY

The prevalence of Cushing’s disease is 39.1 cases/million inhabitants and average incidence is 2.4 cases/million per year.1 The annual incidence rate of endogenous Cushing’s syndrome (CS) has been estimated at 13 cases/million individuals. Of these cases, approximately 70% are due to Cushing’s disease, that is, a pituitary adrenocorticotropin-releasing hormone (ACTH)-producing tumor; 15% to ectopic ACTH and 15% to a primary adrenal tumor. The female-to-male incidence ratio is 5:1. Ectopic ACTH production is found more frequently in men than in women probably because of the increased incidence of lung tumors in the former. The incidence peaks at ages 25–40 years. Increased mortality in CS is likely to be due to cardiovascular disease, higher age, and the persistence of hypertension or diabetes.1

CAUSES AND ASSOCIATED FINDINGS

Glucocorticoid excess (CS) results from either endogenous oversecretion or chronic treatment with glucocorticoids at higher doses. Symptoms of glucocorticoid excess generally occur with the administration of oral steroids, injections of steroids, or inhalers. Patients with diseases (arthritis, allergies, and asthma) that respond to steroid therapy are especially likely to receive steroids and thus develop CS. Indeed, CS are reported even after steroid-based unguents administration.2 Other causes are unilateral or bilateral adrenal hyperplasia, pituitary ACTH secreting adenoma (Cushing’s disease), and ectopic tissues that produce ACTH.

There are similarities between CS and the metabolic syndrome as both are characterized by central obesity, hypertension, insulin resistance, glucose intolerance, and dyslipidemia. Diabetes occurs in approximately 80% of patients with CS but several data are reported about the prevalence of CS in patients with diabetes mellitus.

There are several studies that support the view that unknown CS is not rare among patients with diabetes mellitus.3 Leibowitz et al,4 enrolled in their study 90 diabetic patients with a body mass index >25 and glycosylated hemoglobin >9%, definitely diagnosing CS in three patients (3.3%). Catargi et al5 reported a 2% prevalence of previously unknown CS out of 200 obese patients with type 2 diabetes. Chiodini et al6 demonstrated a higher prevalence of subclinical CS in a cohort of 294 diabetic patients compared with 189 controls (9.4 vs. 2.1%).
This is the first demonstration that screening for CS may be feasible at the clinical onset of diabetes in an unselected cohort of patients. Therefore, early diagnosis and treatment of CS may provide the opportunity to improve the prognosis of diabetes.

Several studies have demonstrated the concomitance of CS and several tumor diseases. They are reported in literature current CS and pheochromocytoma,[7,8] sarcoidosis,[9] pancreatic acinar cell carcinoma,[10] preeclamptic findings,[11] malignant gastrinoma,[12] bronchial carcinoid lung tumor,[13] pancreatic neuroendocrine tumor and Hippel–Lindau disease,[14] and mesenteric neuroendocrine carcinoma.[15]

**Clinical Features and Diagnosis**

The clinical manifestations of CS are variable and multiple as well. Often the patients manifest weight gain, especially in the face, supraclavicular region, and neck. That kind of weight gain produces “moon facies,” “buffalo hump,” and central obesity. Another frequent physical signs are purple striae, skin thinning, and easy bruising. The patients often report difficulties ongoing upstairs, because of proximal muscle weakness. Osteopenia makes the patient prone to spontaneous bone fractures. Amenorrhea, infertility, menstrual irregularities, and decreased libido are some of the clinical manifestation as well. The presence of virilization in women may suggest CS. Due to cortisol, excess sodium and water retention is presented, leading to hypertension. Impairment glucose metabolism and hyperglycemia, metabolic alkalosis, and hypokalemia are common findings in CS. The clinical features are summarized in Table 1.

Cushing disease can be manifested by the above signs and other signs and physical findings because of pituitary adenoma. Pituitary adenoma can cause visual disturbances, head ache, elevated intracranial pressure, and clinical manifestations of pituitary hormones’ oversecretion.

The diagnosis is made using imagery and laboratory tests. The laboratory tests tend to confirm the elevation in plasma, night salivary, and urinary cortisol levels, urinary 17-hydroxycorticosteroids, and plasma ACTH. If one of these test results positive, then the diagnosis is suggested.[16] The next steps consist in several measurements of ACTH and cortisol blood levels in order to determine if it is CS or Cushing’s disease due to pituitary adenoma.[17]

The dexamethasone suppression test serves to determine if the hypersecretion of glucocorticoid is due to pituitary or adrenal gland as well. Pituitary adenoma often is associated with depression in cortisol and 17-hydroxycorticosteroid levels when a high dose of dexamethasone is administered because of negative feedback control, while adrenal tumors do not. Ultrasonography, angio-computed tomography, and magnetic resonance imaging can also confirm the diagnosis. Ectopic glucocorticoid secreting tissues can be also detected using technetium 99-labeled octreotide scintigraphy examinations. Octreotide scintigraphy may be helpful in detecting ectopic ACTH tumors because some neuroendocrine tumors typically have cell surface receptors for somatostatin.[13]

A consensus statement regarding diagnosis was proposed by several authors[18] as presented in Figure 1.

**Medical and Surgical Treatment**

Multidisciplinary teams that involve an endocrinologist, neurosurgeon, general surgeon, or urologist, and anesthesiologist can guarantee the effective diagnosis and management of CS and disease.

Several drugs are used to inhibit the release and synthesis of glucocorticoids. Hypercortisolism can be controlled with adrenal enzyme inhibitors, such as ketoconazole,
The treatment of choice for patients with Cushing’s disease is transsphenoidal microadenomectomy, if a microadenoma is identified. Another non-surgical approach is pituitary irradiation (linear accelerator, gamma knife), and if that fails, bilateral total adrenalectomy is to be performed. Pituitary irradiation also reduces the incidence of Nelson’s syndrome (enlarged, locally invasive, and corticotropin-secreting pituitary tumor).20

Adrenalectomy is also performed when a corticosteroid secretor adrenal hyperplasia is verified. Laparoscopic adrenalectomy remains gold standard but CS is associated with longer hospitalizations, more frequent major complications, and higher advanced care requirements, especially for bilateral adrenalectomy.21 It is generally accepted that the laparoscopic approach offers some advantages, including early return of bowel function, early ambulation, less postoperative pain, low rate of wound infection, and hernia. Several effects are reported during laparoscopy. In the Trendelenburg position (cholecystectomy), the increased IAP can reduce the venous return and cardiac filling pressure, whereas in the anti-Trendelenburg position (prostatectomy) may occur the opposite.22 The blood pressure is usually slightly increased because of carbon dioxide induced increased sympathetic tone and systemic vascular resistance.23 Pneumoperitoneum reduces the splanchic blood flow,24 including renal flow as well. The reduced renal flow leads to reductions in urine output and creatinine clearance.25,26 During laparoscopic surgery, carbon dioxide absorption is a consistent finding in laparoscopic surgery especially during extraperitoneal procedures, such as nephrectomy, adrenalectomy, and hernia repair.27 Pneumoperitoneum worsens the effects of general anesthesia in lung mechanic, such as reduced functional residual capacity, increased intrapulmonary shunts, and increased dead space. The net result may be hypoxemia.28,29 Increased plasma levels of catecholamines, cortisol, renin and, antidiuretic hormone are also verified.30

Anesthetic Considerations

Preoperative optimization and evaluation
It is logical to expect a missing class between American Society of Anesthesia (ASA) 2 and ASA 3 for a systemic disease which is neither mild nor severe but is of moderate nature. Generally CS patients are classified as ASA 2 or 3 because of systemic involvement of the disease [Table 2].

As we cited above, the patients are often hypertensive and hypervolemic. The patients are under chronic antihypertensive drugs also. All the drugs must continue till the morning of surgery except the angiotensin converting enzyme inhibitors (captopril, enalapril, lisinopril, enalaprilat, and ramipril) and angiotensin II receptor blockers (valsartan). These drugs are associated with such severe hypotension with standard anesthetic induction, and under spinal anesthesia also. Clopidrogel should be discontinued 5–7 days before surgery, expect in the coronary-stented patients in which the risk of stent occlusion is high.31,32 The drugs used to inhibit the release and synthesis of glucocorticoids (ketoconazole, metyrapone, mitotane, or aminoglutethimide) must continue preoperatively and discontinue after the surgery.

CS is also associated with hypokalemic metabolic alkalosis. Treating preoperatively the patients with spironolactone will decrease the potassium loss.33

Hyperglycemia is another problem faced by the anesthesiologist in the perioperative period. Increased glucose blood level is found to be associated with increased mortality, higher rates of infections, and longer hospitalization.34–36 Oral agents are generally discontinued before surgery.37 The regimen insulin is necessary to maintain the glucose blood level within the normal values. The anesthesiologist must take care to prevent hypoglycemia as well. The goal is to maintain blood glucose levels within 120–180 mg/dl [6.67 to 10 mmol/l] during the perioperative period.38 The guidelines of American Association of Clinical Endocrinologists and the ADA have recommended target values to 140–180 mg/dl for ICU and 100–180 mg/dl as a target for the diabetic patients in medical and surgical wards.39 In the perioperative period, the regular insulin is the most commonly used one. The doses depend on glucose blood level and the desired target, so frequent glycemia monitoring is mandatory. In order to prevent hypoglycemia, subcutaneous route would be the most suitable choice. The intravenous doses and change rates are summarized in Tables 3 and 4. After the patient starts taking orally liquids, the oral agents substitute the insulin.

Obesity is a major problem faced in CS. Morbidly

| Grade | Description |
|-------|-------------|
| I     | A normal healthy patient |
| II    | A patient with mild systemic disease |
| III   | A patient with severe systemic disease |
| IV    | A patient with severe systemic disease that is a constant threat to life |
| V     | A moribund patient who is not expected to survive without the operation |
| VI    | A declared brain-dead patient whose organs are being removed for donor purposes |

Table 2: American Society of Anesthesia physical status classification

metyrapone, mitotane, or aminoglutethimide, given alone or in combination.30
Predicting difficult intubation is essential. Several parameters such as Mallampati score, mouth opening, neck extension, tireomental and sternomental distances, and Wilson score are used to predict difficult intubation. Generally an obese patient may have normal airways but a higher rate for respiratory failure. A full blood count, electrolytes, renal and liver function tests, and blood glucose form a basic set of investigations. Arterial blood gas analysis may be useful in those suspected of respiratory comorbidity. Pulmonary function test (PFT) is useful to evident the high-risk patient for postoperative respiratory failure. PFT shows the restrictive component of respiratory dysfunction (a normal FEV1/VC, but reduced forced expiratory volume in the first second [FEV1] and vital capacity [VC]). Electrocardiography and echocardiography are essential to estimate stroke volume, LV and RV dimension and contractility, pulmonary hypertension, arrhythmia, and valve structure.

The choice of premedication drugs depends on the anesthesiologist preferences and the physical status of the patient. Preoperative deep sedation in the ward must be avoided because of respiratory failure. The anesthesiologist should promptly secure the airways. As a general rule, a small dose of a benzodiazepine (midazolam 1 mg intravenously) may be sufficient.

**Intraoperative considerations**

Obesity can contribute to increased risk for gastric aspiration. The prevention of gastric aspiration can be realized administering metoklopramide 10 mg, ranitidine 50 mg intravenously, and sodium citrate 30 ml orally just before the induction.

Several possible respiratory complications may be faced. The mask ventilation may be difficult because of obesity. Hypoventilation may occur as a consequence of obesity and proximal muscle weakness, contributing to hypoxia and hypercapnia. The suitable preoxigenation is responsibility of the anesthesiologist and can prevent hypoxia episodes if a difficult intubation occurs.

There are no specific recommendations regarding the anesthetic technique or medication in patients with CS. Sodium thiopentone and propofol can be used. Ketamine should be avoided because of its sympathetic effects. Etomidate blocks the cortisol synthesis and can be used in Cushing’s surgery. The commonly used opioids are fentanyl, sufentanil, and remifentanil as well. It is well-known hypotension and reduced heart rate using remifentanil, but its ultrashort effect can also contribute in reduced respiratory depression and enhanced recovery. Total intravenous anesthesia using the combination of

---

**Table 3: The insulin regimen perioperative therapy**

| Regular insulin | Type 1 DM (male) | Type 1 DM (female) | Type 2 DM |
|-----------------|------------------|--------------------|-----------|
| Initial bolus   | 0.05-0.1 U/kg    | 0.05-0.1 U/kg      | 0.05-0.1 U/kg |
| Infusion        | 1 U/h            | 0.5 U/h            | 1 U/h     |

**Table 4: Glucose blood level and insulin dose changes**

| Glucose blood level (mg/dl) | Infusion rate change (U/h) |
|-----------------------------|-----------------------------|
| ≤70                         | Reassessment within 30 min  |
| 70–120                      | ↓ 0.3                       |
| 121–180                     | No change                   |
| 181–240                     | ↑ 0.3                       |
| 241–300                     | ↑ 0.6                       |
| ≥300                        | ↑ 1                         |

---

obesity is considered when body mass index (body mass index = weight [kg]/height$^2$ [m]) is over 36. Obesity is associated with hypertension, dyslipidemia, ischaemic heart disease, diabetes mellitus, osteoarthritis, liver disease, and obstructive sleep apnea. The cardiorespiratory risk increases with the duration of obesity (fat years). As a result of increased pulmonary blood volume and the adipose tissue around the thoracic cage, lung and chest wall compliances are usually decreased. The reduced compliance contributes in FRC reduction, atelectasis, ventilation/perfusion (V/Q) mismatching, intrapulmonary shunt, and finally hypoxemia and rapid desaturation. Blood volume, cardiac output, ventricular workload, oxygen consumption, and CO$_2$ production are all increased. These may lead to systemic and pulmonary hypertension and later cor pulmonale and right ventricular failure. The increased left ventricular (LV) wall stress and hypertrophy are secondary to systemic hypertension, later resulting in LV dilatation. Finally, the ischemic heart disease is a common finding in obese patients.

Hypertension, obesity, hyperglycemia, inability to make a normal physical activity, and hypercoagulable state can also contribute to increased risk for deep venous thrombosis and pulmonary embolism (PE). The prevention of perioperative venous thromboembolism and PE can be realized using low-molecular weight heparin (enoxaparin, dalteparin, etc.) or fondaparinux, and lower extremity compression devices. Warfarin is also recommended in high-risk patients. Early mobilization is also essential and very useful.

Because of osteopenia and easy bruisability, the anesthesiologist must take care during positioning and taping the patient, in order to prevent bone fractures and skin damages.

---

Indian Journal of Endocrinology and Metabolism / 2011 / Vol 15 / Supplement 4
opiates are used for postoperative analgesia, a loading dose effective in controlling postoperative pain. If epidural loss, and the incidence of PE. Epidural analgesia is also respiratory complications, proinflammatory response, has been demonstrating to reduce the surgery-induced cases for its use in CS are reported.

The use of epidural anesthesia is helpful although few bacterial colonization of each institute. The prophylaxis is mainly based on own protocols and antibiotics is mandatory in order to prevent the infections. opportunistic infections.

The endogenous production of excessive amounts of glucocorticoids has also been described as the stimulus for immunosuppression, with resultant development of opportunistic infections. So the prophylaxis with right antibiotics is mandatory in order to prevent the infections. The prophylaxis is mainly based on own protocols and bacterial colonization of each institute.

The use of epidural anesthesia is helpful although few cases for its use in CS are reported. Using epidural has been demonstrating to reduce the surgery-induced proinflammatory response, the cardiovascular and respiratory complications, the intraoperatively blood loss, and the incidence of PE. Epidural analgesia is also effective in controlling postoperative pain. If epidural opiates are used for postoperative analgesia, a loading dose of hydromorphone (0.5–1.0 mg) is usually administered 1 h before the end of surgery.

During the laparoscopic adrenalectomy, the anesthesiologist must take care of hemodynamic perturbations (rationally filling the patient) and laparoscopic respiratory consequences (modifying the ventilator parameters related to capnography changes).

Transsphenoidal resection is the surgical technique applied when an ACTH pituitary tumor is verified (Cushing’s disease). Standard precautions regarding difficult intubation or ventilation and monitoring are also recommended. The muscle relaxant dose must be reduced. With adequate anesthesia and the head in the Mayfield–Kees skeletal fixation, the movements are unlikely. The anesthesiologist must use a reinforced endotracheal tube, to prevent kinking while the surgeon is working. Before the extubation, the anesthesiologist must be assured that all the blood accumulated in the back of the throat is suctioned out. Replacement therapy with steroids is necessary until the pituitary normal function return. Occasionally patients may develop diabetes insipidus which is treated with prompt fluid administration and vasopressin therapy.

The patient should be alert, warm, hemodynamically stable, and fully reversed from muscle relaxants before the extubation. Table 5 summarizes the most important issues to do or to avoid.
**Table 5: The most important thing to do, or not to do**

| Remember to do | Remember not to do |
|----------------|--------------------|
| Airway evaluation | Not preoperative deep sedation |
| Careful cardiovascular evaluation (ECG, ECHO) | Excessive dose of muscle relaxants |
| Careful respiratory evaluation (X-ray, blood gases, PFT) | Incorrect patient position |
| Stabilize glycemia (insulin regimen) | Aggressive taping |
| Acid base and electrolytes corrections (spironolactone, potassium) | |
| Prevention of gastric aspiration (metoklopramide, ranitidine, sodium citrate) | |
| Invasive monitoring | |
| Infection prophylaxis | |
| Extubate when the patient is alert, warm, hemodynamically stable, and fully reversed from muscle relaxants | |
| Routinely postoperative monitoring of cortisol, glycemia, and electrolytes | |
| Prevention of cortisol deficiency (hydrocortisone succinate) | |
| After the hospital discharged, the patient must be referred to the endocrinologist | |

---

**CONCLUSION**

Surgery in CS presents a challenge to the anesthesiologist. The control of perioperative hypertension, hyperglycemia, hypokalemia, and cortisol blood level are hallmarks of the anesthesiologist’s role treating the patients with Cushing’s syndrome.

**REFERENCES**

1. Ekabé J, Vazquez JA. Morbidity and mortality in Cushing’s disease: An epidemiological approach. Clin Endocrinol (Oxf) 1994;40:479-84.
2. Semz S, Balcı YI, Ergin S, Candemir M, Polat A. Two cases of Cushing’s syndrome due to overuse of topical steroid in the diaper area. Pediatr Dermatol 2008;25:544-7.
3. Reimondo G, Pins A, Allasino B, Tassone F, Bossio S, Bonetta G, et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf) 2007;67:225-9.
4. Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, et al. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996;44:717-22.
5. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 2008;88:5808-13.
6. Chiodini I, Tortolomato M, Scillitani A, Arosio M, Bacci S, Di Lembo S, Epaminonda P, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: A case-control study in hospitalized patients. Eur J Endocrinol 2005;153:837-44.
7. Bayarakta F, Kebapcilar L, Kocodor MA, Asa SL, Yesil S, Canda S, et al. Cushing’s syndrome due to ectopic CRH secretion by adrenal pheochromocytoma accompanied by renal infarction. Exp Clin Endocrinol Diabetoses 2006;114:444-7.
8. Kumar M, Kumar V, Talukdar B, Mohta A, Khurana N. Cushing syndrome in an infant due to cortisol secreting adrenal pheochromocytoma: A rare association. J Pediatr Endocrinol Metab 2010;23:621-5.
9. Schaefer S, Meyer S, Bruack CC, Weber M, Lueddecke D, Wagner HJ, et al. Sarcoïdosis following Cushing’s syndrome: A report of two cases and review of the literature. Exp Clin Endocrinol Diabetes 2010;118:147-50.
10. Illyés G, Luczay A, Benyó G, Kalmán A, Borka K, Köves K, et al. Cushing’s syndrome in a child with pancreatic acinar cell carcinoma. Endocr Pathol 2007;18:95-102.
11. Delibasi T, Ustun I, Aydin Y, Berker D, Erol HK, GUL K, et al. Early severe pre-eclamptic findings in a patient with Cushing’s syndrome. Gynecol Endocrinol 2006;22:710-2.
12. Park SY, Rhee Y, Youn JC, Park YN, Lee S, Kim DM, et al. Ectopic Cushing’s syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma. Exp Clin Endocrinol Diabetes 2007;115:13-6.
13. Esfahani AF, Chavoshi M, Noorani MH, Saghari M, Eftekhari M, Beiki D, et al. Successful application of technetium-99m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropic-producing bronchial carcinoid lung tumor: A case report. J Med Case Reports 2010;4:323.
14. Benitez Velazo C, Pacheco Capote C, Latre Romero JM. Ectopic Cushing’s syndrome caused by a functioning pancreatic neuroendocrine tumour in a patient with von Hippel-Lindau disease. Rev Esp Med Nucl 2008;27:29-33.
15. Fasshauer M, Lincke T, Witzigmann H, Kluge R, Tannapfel A, Moche M, et al. Ectopic Cushing’s syndrome caused by a neuroendocrine carcinoma of the mesentery. BMC Cancer 2006;6:108.
16. Newill-Price J, Bertogna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605-17.
17. Vaughan ED Jr. Diseases of the adrenal gland. Med Clin North Am 2004;88:443-66.
18. Arnaldi G, Angelini A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: A consensus Statement. J Clin Endocrinol Metab 2003;88:5593-602.
19. Díez JJ, Iglesias P. Pharmacological therapy of Cushing’s syndrome: Drugs and indications. Mini Rev Med Chem 2007;7:467-80.
20. Gil-Cárdenas A, Herrera MF, Díaz-Polanco A, Rios JM, Pantoja JP. Nelson’s syndrome after bilateral adrenalectomy for Cushing’s disease. Surgery 2007;141:147-52.
21. Kissane NA, Cendan JC. Patients with Cushing’s syndrome are care-intensive even in the era of laparoscopic adrenalectomy. Am Surg 2009;75:279-83.
22. Joris JL, Noirot DP, Legrand MJ, Jacquet NJ, Lamy ML. Hemodynamic changes during laparoscopic cholecystectomy. Anesth Analg 1993;76:1067-71.
23. Reid CW, Martineau RJ, Hull KA, Miller DR. Hemodynamic consequences of abdominal insufflation with CO2 during laparoscopic cholecystectomy. Can J Anaesth 1992;39:A132.
24. Junghans T, Bohm B, Grundel K, Schweng W, Müller JM. Does pneumoperitoneum with different gases, bodypositions and consequences of abdominal insufflation with CO2 during laparoscopic cholecystectomy? J Anesth Analg 1997;121:206-11.
25. Koivusalo AM, Kellokumpu I, Ristkari S, Lindgren L. Splanchnic and intraperitoneal pressures influence renal and hepatic flow? Surgery 1997;121:206-11.
26. Lindberg F, Bergqvist D, Bjorck M, Rasmussen I. Renal hemodynamics
during carbon dioxide pneumoperitoneum: An experimental study in pigs. Surg Endosc 2003;17:480-4.
27. Streich B, Decaillot F, Ferney C, Duvaldestin P. Increased carbon dioxide absorption during retroperitoneal laparoscopy. Br J Anaesth 2003;91:793-6.
28. Hedenstierna G. Gas exchange during anaesthesia. Br J Anaesth 1990;64:507-14.
29. Drummond GB, Martin LV. Pressure volume relationships in the lung during laparoscopy. Br J Anaesth 1978;50:261-70.
30. Donald RA, Perry EG, Wittert GA, Chapman M, Livesey JH, Ellis MJ, et al. The plasma ACTH, AVP, CRH and catecholamine responses to conventional and open cholecystectomy. Clin Endocrinol (Oxf) 1993;38:609-15.
31. Kang W, Theman TE, Reed JF 3rd, Stoltzfus J, Weger N. The effect of preoperative clopidogrel on bleeding after coronary artery bypass surgery. J Surg Educ 2007;64:88-92.
32. Price J, Tadbiri S. Aspirin and clopidogrel use in perioperative period for non-cardiac surgery. Br J Hosp Med (Lond) 2008;69:56.
33. Ural AU, Avcu F, Cetin T, Beyan C, Kaptan K, Nazaroglu NK, Yalcin A. Spironolactone: Is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? Eur J Clin Pharmacol 2002;57:771-3.
34. Bochicchio GV, Sung J, Yoshi M, Bochicchio K, Johnson SB, Meyer W, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 2005;58:921-4.
35. Pompomelli JJ, Baxter JK 3rd, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 1998;22:77-81.
36. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 2002;40:418-23.
37. Marks JB. Perioperative management of diabetes. Am Fam Physician 2003;67:93-100.
38. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009;15:353-69.
39. Lotia SH, Bellamy M. Anaesthesia and Morbid Obesity: Postoperative Considerations. Cont Edu Anaesth Crit Care and Pain 2008;8:151-6.
40. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 (6 Suppl):381S-453S.
41. Ugur B, Ogurlu M, Gezer E, Nuri Aydin O, Gunsoy F. Effects of esmolol, lidocaine and fentanyl on haemodynamic responses to endotracheal intubation: A comparative study. Clin Drug Investig 2007;27:269-77.
42. Domi R. The best prediction test of difficult intubation. J Anaesth Clin Pharmacol 2010;26:193-6.
43. Yusa T, Sasara T, Taira Y, Shiroma H, Shimabukuro H. The anesthetic management for adrenalectomy of a patient with Cushing’s syndrome in pregnancy. Masui 1992;41:1168-74.
44. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62.
45. Moselli MN, Baricocchi E, Ribero D, Sottile A, Suita L, Debernardi F. Intraoperative Epidural Analgesia Prevents the Early Proinflammatory Response to Surgical Trauma. Results from a Prospective Randomized Clinical Trial of Intraoperative Epidural versus General Analgesia. Ann Surg Oncol 2011 [In press].
46. Svircevic V, van Dijk D, Nierich A, Passier M, Kallman C, van der Heijden G, et al. Meta-analysis of thoracic epidural anesthesia versus general anesthesia for cardiac surgery. Anesthesiology 2011;114:271-82.
47. Ozyuvaci E, Altan A, Karadeniz T, Topsakal M, Besisik A, Yucel M. General anesthesia versus epidural and general anesthesia in radical cystectomy. Urol Int 2005;74:62-7.

Cite this article as: Domi R. Cushing’s surgery: Role of the anesthesiologist. Indian J Endocr Metab 2011;15:322-8.
Source of Support: Nil, Conflict of Interest: None declared.